武漢佰樂(lè)博代理：Research Grade labetuzumab
貨號(hào)：DHC21001
產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75486.html
產(chǎn)品購(gòu)買聯(lián)系方式：027-65279366
產(chǎn)品介紹：Labetuzumab是一種人源化抗癌胚抗原(CEA)單克隆抗體，可抑制腫瘤生長(zhǎng)并使人類髓樣甲狀腺癌異種細(xì)胞對(duì)Dacarbazine化療敏感。
通用名：Labetuzumab
純度：>95% by SDS-PAGE.
濃度：1mg/ml
Formulationicon：0.01M PBS, pH 7.4.
內(nèi)毒素：Please contact with the lab for this information.
別名：hMN14, IMMU-130, hMN-14-SN-38, hMN-14-SN-38 ADC, hMN14-CL-SN-38, Labetuzumab Govitecan
靶點(diǎn);物種：Human CD66e/CEA/CEACAM5
種類：Humanized
受體鑒定：IgG1-kappa
CAS: 219649-07-7
參考文獻(xiàn)：
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. PMID: 28817371
Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. PMID: 10647610
Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. PMID: 9441773
Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. PMID: 30822636
Labetuzumab govitecan in metastatic colorectal cancer. PMID: 28844817
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. PMID: 33199493
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. PMID: 28817371
Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). PMID: 29079710
Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. PMID: 28126888
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. PMID: 19789330
Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin. PMID: 35551444
Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. PMID: 17570017
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. PMID: 16170184
Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. PMID: 15592930
Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies. PMID: 31533926
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. PMID: 15634649
Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study. PMID: 27763687
Development of humanized antibodies as cancer therapeutics. PMID: 15848077
Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. PMID: 25402018
Gateways to clinical trials. PMID: 15672123
SPECT- and fluorescence image-guided surgery using a dual-labeled carcinoembryonic antigen-targeting antibody. PMID: 24982436
Multimodal treatment options for bilobar colorectal liver metastases. PMID: 20213463
Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy. PMID: 15632046
A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. PMID: 15809485
In vitro and in vivo anticancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies. PMID: 18728675
Radioimmunotherapy for liver metastases. PMID: 17726786
Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. PMID: 12918078
Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats. PMID: 12954123
Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. PMID: 9441773
Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. PMID: 10647610
Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. PMID: 10223579
Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. PMID: 12453334
Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. PMID: 15002034
